Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HLA-B*57: 01 genotyping in the prevention of hypersensitivity to abacavir: 5 years of experience.

Pharmacogenetics and genomics - 1 Aug 2016

Ruiz-Iruela Cristina, Padullés-Zamora Núria, Podzamczer-Palter Daniel, Alonso-Pastor Arnald, Candás-Estébanez Beatriz, Alía-Ramos Pedro, Padró-Miquel Ariadna

Abstract excerpt

INTRODUCTION: Most of the cost-effectiveness analyses are based on estimations to make decisions on the future implementation of a test. However, the model should be verified with real data to prove that previous estimations have been successfully fulfilled. OBJECTIVE: To study the economic impact of the systematic HLA-B*57:01 genotyping in preventing hypersensitivity reactions (HSRs) in the patient population of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Cost-Benefit Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dideoxynucleosides

Share to Drug Hypersensitivity

Share to HIV Seropositivity

Share to HLA-B Antigens

Share to Pharmacogenetics

Source

Identifiers

PMID: 27195528
DOI: 10.1097/FPC.0000000000000229

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HLA-B*57: 01 genotyping in the prevention of hypersensitivity to abacavir: 5 years of experience.PMID 27195528Read ↗

Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity.Semantic proximity Read ↗

Reducing hypersensitivity reactions with HLA-B*5701 genotyping before abacavir prescriptionSemantic proximity Read ↗

Cost-effectiveness analysis of HLA-B*5701 typing in the prevention of hypersensitivity to abacavir in HIV+ patients in SpainSemantic proximity Read ↗

Global Frequencies of Clinically Important HLA Alleles and Their Implications For the Cost-Effectiveness of Preemptive Pharmacogenetic Testing.Semantic proximity Read ↗

HCP5 rs2395029 is a rapid and inexpensive alternative to HLA-B*57:01 genotyping to predict abacavir hypersensitivity reaction in Spain.Semantic proximity Read ↗

HLA-B*5701 screening for hypersensitivity to abacavir.Semantic proximity Read ↗

Direct PCR: a new pharmacogenetic approach for the inexpensive testing of HLA-B*57:01.Semantic proximity Read ↗

Association of HLA-B*5701 genotypes and abacavir-induced hypersensitivity reaction: a systematic review and meta-analysis.Semantic proximity Read ↗

Abacavir Pharmacogenetics – From Initial Reports to Standard of CareSemantic proximity Read ↗

Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicineSemantic proximity Read ↗

Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.Semantic proximity Read ↗

Novel Sensitive, Specific and Rapid Pharmacogenomic test for the Prediction of Abacavir Hypersensitivity Reaction: HLA-B*57:01 Detection by Real-Time PCRSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.